Latest Hyperphosphatemia News
At 18 months, PTH levels were within target for 67% and 68% of participants who initiated etelcalcetide at 2.5 mg and 5 mg, respectively.
Nearly twice as many patients achieved the target phosphorus range after a year of taking the phosphate binder, regardless of iPTH level.
Replacing foods containing phosphorus-based additives with similar foods not containing these additives can control hyperphospatemia without interfering with nutritional status.
Alkaline phosphatase was more strongly linked to mortality compared with other biomarkers of chronic kidney disease-mineral and bone disorder.
In a study, 25.8% and 37.8% of calcium acetate and calcium carbonate users, respectively, exceeded the maximum recommended daily intake.
In a study 52.1% of patients receiving ferric citrate attained a 1.0 g/dL or greater increase in hemoglobin compared with just 19.1% receiving placebo.
Younger patients are less likely to respond to treatment with sucroferric oxyhydroxide or sevelamer.
Purgative products introduce 10 times the normal daily amount of phosphorus into the body.
Study implicates amlodipine, lisinopril, clonidine, acetaminophen, and omeprazole.
Patients also needed fewer phosphate binder pills over time.
The percentage of patients with serum phosphorus levels of 5.5 mg/dL and below more than doubled to 37.8% after 6 months of treatment with sucroferric oxyhydroxide.
The risk of end-stage renal disease was 83% higher for those who drank more than 7 glasses of diet soft drinks weekly.
It can sharply lower serum phosphorus levels and reduce dependence on phosphate binders.
In a study, 69.7% of intervention patients attained serum phosphorus levels below 5.5 mg/dL, compared with just 18.5% of control patients.
A low protein, low phosphorus diet plays an important role in the nutritional management of patients transitioning to once-weekly incremental hemodialysis.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)